Rosanna Sutherby, Pharm.D.

Articles

Bayer Receives FDA Fast-Track Designation for Next-Generation Anticoagulant

February 18, 2022

Asundexian is an oral factor XIa inhibitor currently under phase 2 trials for potential secondary thrombosis prevention in patients with non-cardioembolic ischemic stroke, atrial fibrillation, or recent myocardial infarction.